When the results of the study of FBT by Portenoy et al. [ 14] are compared with that in the FBSF study, it is apparent that the response to placebo was consistently higher in our trial [e.g., placebo PID at 30 min was 36% higher in this trial than in the buccal tablet trial (1.9 versus 1.4)].
Data from six previously published randomized, placebo-controlled grass SLIT-tablet trials (6– 14) conducted in Europe and North America were used to evaluate the association between rhinoconjunctivitis symptoms and pollen exposure and its impact on the measured efficacy.
Ethics approval for the HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial (HEMATOCRIT trial) has been obtained from the local Institutional Ethics Committee in all participating centres prior to study initiation and patient enrolment.
One phase III grass SLIT-tablet trial was omitted from the pooled analysis as post hoc findings suggested that the symptoms and medication use reported in the trial were not primarily reflective of the effects of grass pollen exposure.
Because of the frequency of non-serious adverse events associated with methylphenidate, the particular difficulties for blinding of participants and outcome assessors point to the advantage of large, "nocebo tablet" controlled trials.
In the SPIRIT (Switching boosted PI to Rilpivirine In-combination with Truvada as a single tablet regimen) trial, improvement in lipid parameters was demonstrated in 476 subjects, 24 weeks after switching to a rilpivirine-based regimen.
Withdrawal criteria: Renal transplantation, non-compliance, clinical complications rendering oral ingestion of tablets or trial completion impossible, transferral to another dialysis department and withdrawal of informed consent.
24 Nifedipine was administered as a capsule (eight trials), tablet (three trials; one was a comparison of capsule versus tablet), or the formulation was unclear (two trials).
Trials were conducted using the one-pot procedure (Supplement 2) on Sudafed® tablets (control) and Impede™ technology tablets (test).
Omadacycline started enrollment in a phase 3 ABSSSI trial in 2009 with 200 mg IV, with potential to step-down to a 150 mg oral tablet, but the trial was stopped to change their endpoints in the protocol to be as required by the new FDA guidance for trial on cSSTI.
Trial drug was administered without a dose reduction to 31 out of 60 patients during the first three cycles of chemotherapy; of these 14 patients omitted at least one tablet of the trial drug.
